Blastic Plasmacytoid Dendritic Cell Neoplasm An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 34-3 - May 5, 2020
Author: Andrew A. Lane
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 2 2 6 0 - 5
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 2 2 6 5 - 0

This issue of Hematology/Oncology Clinics, guest edited by Andrew A. Lane, will cover Blastic Plasmacytoid Dendritic Cell Neoplasm. This issue is one of six selected each year by… Read more

Blastic Plasmacytoid Dendritic Cell Neoplasm An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Hematology/Oncology Clinics, guest edited by Andrew A. Lane, will cover Blastic Plasmacytoid Dendritic Cell Neoplasm. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue include: Clinical Presentation and Pathology, Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA mutations and epigenetics, Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm Chemotherapy, CD123 and Leukemia Stem Cells, Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm, Immune Therapies Targeting CD123 in Blastic Plasmacytoid Dendritic Cell Neoplasm, Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm in Children, European Perspective, Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm, and Social Media in Blastic Plasmacytoid Dendritic Cell Neoplasm and Other Rare Diseases.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis
Key points
Diagnosis of blastic plasmacytoid dendritic cell neoplasm in clinical practice
Summary
Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective
Key points
Introduction
Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm
Differential diagnosis
Biopsy approach and histopathologic features
Evaluation and prognosis of the blastic plasmacytoid dendritic cell neoplasm patient
Blastic plasmacytoid dendritic cell neoplasm treatment
Summary
Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics
Key points
Introduction
DNA mutations
Epigenetic pathway gene mutations
Clinical impact of epigenetic mutations
Epigenetics
Summary
Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations
Key points
Introduction
Summary
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
Key points
Introduction
Intensive chemotherapy for fit individuals
Non-fit individuals
Summary
CD123 as a Therapeutic Target Against Malignant Stem Cells
Key points
Introduction
CD123 in normal hematopoietic cells and normal tissues
CD123 expression in malignancies
CD123 targeting in other malignancies
Summary
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm
Key points
Introduction
Literature review
Mechanism of action
Preclinical development
Clinical experience in adults
Pediatric blastic plasmacytoid dendritic cell neoplasm: clinical experience in children
Context for the early clinical experience
Next steps: rational combination therapy
Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm
Key points
Introduction: blastic plasmacytoid dendritic cell neoplasm and CD123
CD123 chimeric antigen receptor T cell immunotherapy
Recombinant fusion protein: SL-401
Antibody-drug conjugate: IMGN632
Bispecific antibody: XmAb14045
Potential resistance mechanism
Checkpoint blockade: nivolumab
Summary
Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm
Key points
Introduction
BPDCN genetics have not yet revealed a universally shared therapeutic target
BPDCN depends on BCL2 and is sensitive to the BCL2 inhibitor venetoclax
Combinations with tagraxofusp
Transcription factors and epigenetic machinery as targets
Drugs in clinical use or in development for other cancers
Summary and areas for improvement
Blastic Plasmacytoid Dendritic Cell Neoplasm in Children
Key points
Introduction
Pathophysiologic and pathologic features
Clinical presentations
Diagnosis and differential diagnosis
Treatment
Discussion
Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective
Key points
Introduction
The French experience
The European perspective
Summary
Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm
Key points
Introduction
Hematopoietic cell transplant for blastic plasmacytoid dendritic cell neoplasm
Discussion